Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.repc.2020.07.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optical coherence tomography characterization of degradation kinetics between second- and third-generation resorbable magnesium scaffold.
Catheter Cardiovasc Interv
November 2024
Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technical University Munich, Munich, Germany.
Aims: This preclinical study aimed to establish optical coherence tomography (OCT)-derived parameters that could be used in the clinical setting for assessing strut degradation in the third-generation drug-eluting resorbable magnesium scaffold (DREAMS-3G), and characterize the comparative degradation profile against its precursor device (Magmaris scaffold).
Methods And Results: Twelve DREAMS-3G and 10 Magmaris scaffolds were implanted in juvenile pigs, and OCT images obtained at baseline and follow-up (6 or 12 months). Strut degradation was assessed by planimetric analysis and compared with OCT-derived indices to validate their diagnostic accuracy.
In vivo chronic scaffolding force of a resorbable magnesium scaffold.
J Biomech
February 2024
German Heart Center Munich, Lazarettstraße 36, 80636 München, Germany. Electronic address:
The aim of this study is to qualitatively characterize the in vivo chronic scaffolding force of the Magmaris® Resorbable Magnesium Scaffold (RMS). This important parameter of scaffolds must be balanced between sufficient radial support during the healing period of the vessel and avoidance of long-term vessel caging. A finite element model was established using preclinical animal data and used to predict the device diameter and scaffolding force up to 90 days after implantation.
View Article and Find Full Text PDFTwo-year clinical outcomes of resorbable magnesium scaffold versus conventional drug-eluting stents in ST-segment elevation myocardial infarction: A propensity score matching analysis.
Hellenic J Cardiol
July 2024
Department of Cardiology, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium. Electronic address:
Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry.
Cardiovasc Revasc Med
December 2023
Cardiologia Invasiva 2, Centro Cardiologico Fondazione Monzino, IRCCS, Università di Milano, Italy.
Background: The magnesium Magmaris scaffold is the latest resorbable technology with low thrombogenicity, short scaffolding time, and almost complete resorption at 12 months (95 %). As compared with stable coronary artery disease (SCAD), acute coronary syndrome (ACS) is associated with increased risk of adverse clinical outcome after percutaneous coronary intervention. We analyzed the data of the Magmaris Multicenter Italian Registry to compare clinical outcomes in SCAD versus ACS patients.
View Article and Find Full Text PDFA new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
EuroIntervention
August 2023
Interventional Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA.
Article Synopsis
- The DREAMS 3G is a new coronary magnesium scaffold designed to match the performance of traditional drug-eluting stents (DES).
- The BIOMAG-I study is a first-in-human trial that evaluates the safety and effectiveness of this scaffold with a follow-up period of up to 5 years.
- Results showed that after 12 months, the scaffold demonstrated low rates of complications, confirming its safety and efficacy as a potential alternative to DES.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!